Cookie preferences
This website uses cookies, which are necessary for the technical operation of the website and are always set. Other cookies, which increase the comfort when using this website, are used for direct advertising or to facilitate interaction with other websites and social networks, are only set with your consent.
Configuration
Technically required
These cookies are necessary for the basic functions of the shop.
"Allow all cookies" cookie
"Decline all cookies" cookie
CSRF token
Cookie preferences
Currency change
Customer-specific caching
FACT-Finder tracking
Individual prices
Selected shop
Session
Comfort functions
These cookies are used to make the shopping experience even more appealing, for example for the recognition of the visitor.
Note
Show the facebook fanpage in the right blod sidebar
Statistics & Tracking
Affiliate program
Conversion and usertracking via Google Tag Manager
Track device being used

If you have any questions, please use our Contact Form.
You can also order by e-mail: info@biomol.com
Larger quantity required? Request bulk
You can also order by e-mail: info@biomol.com
Larger quantity required? Request bulk
Tirofiban is a potent nonpeptide glycoprotein IIb/IIIa antagonist (GPIIb/IIIa, IC50 = 5 nM in a... more
Product information "Tirofiban (hydrochloride hydrate)"
Tirofiban is a potent nonpeptide glycoprotein IIb/IIIa antagonist (GPIIb/IIIa, IC50 = 5 nM in a radioligand binding assay). It inhibits GPIIb/IIIa-dependent platelet aggregation with an IC50 value of 11 nM. Tirofiban is selective for platelet GPIIb/IIIa, only inhibiting human umbilical vein endothelial cell (HUVEC) attachment to microtiter plates containing fibrinogen (Fg), human vitronectin (Vn), or human fibronectin (Fn) at concentrations >10,000-fold above the IC50 for platelet aggregation. Tirofiban (300 and 1,000 µg/kg per minute, i.v.) prevents occlusive thrombosis and reduces thrombus mass in a canine model of electrically-induced coronary artery occlusive thrombosis. Formulations containing tirofiban have been used to prevent thrombotic occlusion associated with coronary angioplasty.Formal Name: N-(butylsulfonyl)-O-[4-(4-piperidinyl)butyl]-L-tyrosine, monohydrochloride, monohydrate. CAS Number: 150915-40-5. Molecular Formula: C22H36N2O5S . HCl [H2O]. Formula Weight: 495.1. Purity: >98%. Formulation: (Request formulation change), A crystalline solid. Solubility: DMF: 30 mg/ml, DMSO: 30 mg/ml, Ethanol: 30 mg/ml, Ethanol:PBS (pH7.2)(1:20): 0.05 mg/ml. lambdamax: 228, 277 nm. SMILES: O=C(O)[C@@H](NS(CCCC)(=O)=O)CC1=CC=C(OCCCCC2CCNCC2)C=C1.Cl.O. InChi Code: InChI=1S/C22H36N2O5S.ClH.H2O/c1-2-3-16-30(27,28)24-21(22(25)26)17-19-7-9-20(10-8-19)29-15-5-4-6-18-11-13-23-14-12-18,,/h7-10,18,21,23-24H,2-6,11-17H2,1H3,(H,25,26),1H,1H2/t21-,,/m0../s1. InChi Key: HWAAPJPFZPHHBC-FGJQBABTSA-N.
Keywords: | N-(butylsulfonyl)-O-[4-(4-piperidinyl)butyl]-L-tyrosine, monohydrochloride, monohydrate |
Supplier: | Cayman Chemical |
Supplier-Nr: | 23392 |
Properties
Application: | Platelet aggregation inhibitor, Glycoprotein IIb/IIIa receptor antagonist |
MW: | 495.1 D |
Formula: | C22H36N2O5S . HCl [H2O] |
Purity: | >98% |
Format: | Crystalline Solid |
Database Information
CAS : | 150915-40-5| Matching products |
KEGG ID : | K06493 | Matching products |
Handling & Safety
Storage: | -20°C |
Shipping: | +20°C (International: -20°C) |
Signal Word: | Warning |
GHS Hazard Pictograms: |
![]() |
H Phrases: | H302, H315, H319, H335 |
P Phrases: | P261, P264, P270, P271, P280, P312, P321, P330, P301+P310, P302+P352, P304+P340, P305+P351+P338, P332+P313, P337+P313, P362+P364, P405, P403+P233, P501 |
Caution
Our products are for laboratory research use only: Not for administration to humans!
Our products are for laboratory research use only: Not for administration to humans!
Information about the product reference will follow.
more
You will get a certificate here
Viewed